UroGen Pharma furnishes January 2025 corporate presentation; no material new disclosures

UroGen Pharma Ltd.

Presentation reiterates UGN-102 PDUFA target date of June 13, 2025 and planned ODAC meeting.
Highlights ongoing Phase 3 UTOPIA study for UGN-103 and planned Phase 3 for UGN-104.
No new financial data or material changes disclosed.

item 7.01 item 9.01

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-25-005649

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.